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INTRODUCTION
Cardiovascular disease remains the major cause of death in developed
countries, with atherosclerosis leading to approximately 650,000 myocardial
infarctions (MI) each year in the United States.
While the current diagnostic gold standard for coronary artery disease (CAD)
is coronary angiography via cardiac catheterization, less invasive blood tests
identifying a regulatory T regulatory cell (Treg) imbalance have shown
impressive sensitivity and specificity for CAD.
Whole blood RNA analyses via single-molecule next-generation sequencing
(NGS) of RNA (RNAseq) have identified transcripts associated with CAD
(TRACs) that illustrate an mRNA signature of a Treg-like defect in CAD
patients.

METHODOLOGY
Whole blood RNA was analyzed by single-molecule next-generation
sequencing (NGS) of RNA (RNA-Seq) to identify TRACs in a discovery group
and a validation group presenting for coronary catheterization.
Whole blood RNA was depleted of ribosomal RNA (rRNA) and then
sequenced on a SeqLL Single Molecule Sequencer. The resulting short
reads were aligned to the human transcriptome and the number of reads
per kilobase of exon per million (RPKM) was determined and compared
between groups by a combined fold-change/p-value filter.
This model was replicated in an additional study, and an identical design
was undertaken using a sequencer from Illumina, and transcript reads
were analyzed by sequencer product.

Results have been variable, however, based on the specific single molecule
sequencer product employed. The prospect of an accurate and reliable blood
test to predict the development of atherosclerosis excites many and would
fundamentally alter the diagnostic landscape for CAD.

RESULTS
Sequencing identified a profile of Treg imbalance in patients
with even mild coronary stenosis (>20%) as confirmed on
coronary angiography. The SeqLL platform identified a subset of
39 transcripts highly-associated with CAD that were replicated
in a follow-up study (p<0.001). The Illumina follow-up study
also identified a similar sized set of transcripts related to T cell
dysfunction. In a replication analysis with the Illumina platform,
roughly the same number of transcripts were confirmed in a
similar sized cohort of about 100 patients. However, there was
not any significant overlap in the exact transcripts identified by
the two different next-generation sequencing platforms.

CONCLUSION
The SeqLL sequencing platform of amplification-free, single
molecule sequencing identifies different transcripts associated
with CAD than the amplification-dependent Illumina NextSeq.
Each platform identifies its own subset of transcripts that
reproduce between 2 distinct cohorts, and these transcripts are
consistently associated with the T regulatory cell phenotype.
Future investigations will be directed toward establishing a
clinically relevant amplification-free method of quantifying RNA
in patient blood.

OBJECTIVE
The objective of the project was to determine the degree of reproducibility
among the primary techniques previously used to identify and quantify the
Treg imbalance underlying atherosclerosis.
Specifically, the single molecule sequencer from SeqLL and that from Illumina
have been utilized previously and reflect some heterogeneity in their results.
This knowledge would enable investigators to discern superior techniques
and ultimately empower clinicians and to make use of the most reliable
methods.

Figure 1. Strategy to identify blood RNA biomarkers of CAD.
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Figure 2. Schematic representation of of Treg-related TRACs
identified by RNA-Seq.

